Publications

The cellular prion protein (PrP (c)) plays many roles in the developing and adult brain. In addition, PrP (c) binds to several amyloids in oligomeric and prefibrillar forms and may act as a putative receptor of abnormal misfolded protein species. The role of PrP (c) in tau seeding and spreading is not known. In the present study, we have inoculated well-characterized sarkosyl-insoluble fractions of sporadic Alzheimer's disease (sAD) into the brain of adult wild-type mice (Prnp(+/+)), Prnp(0/0) (ZH3 strain) mice, and mice over-expressing the secreted form of PrP (c) lacking their GPI anchor (Tg44 strain). Phospho-tau (ptau) seeding and spreading involving neurons and oligodendrocytes were observed three and six months after inoculation. 3Rtau and 4Rtau deposits from the host tau, as revealed by inoculating Mapt(0/0) mice and by using specific anti-mouse and anti-human tau antibodies suggest modulation of exon 10 splicing of the host mouse Mapt gene elicited by exogenous sAD-tau. However, no tau seeding and spreading differences were observed among Prnp genotypes. Our results show that PrP (c) does not affect tau seeding and spreading in vivo.

JTD Keywords: Alpha-synuclein, Alzheimer disease, Alzheimer's disease, Alzheimer’s disease, Amyloid-beta oligomers, Animals, Brain, Disease models, animal, Expression, Humans, Impairmen, Mapt, Mice, Mice, transgenic, Neurons, Paired helical filaments, Pathological tau, Prion proteins, Prnp, Prnp protein, mouse, Propagation, Prp (c), Prpc, Prpc proteins, Sarcosine, Sarkosyl, Seeding, Spreadin, Spreading, Synaptic plasticity, Tau, Tau proteins, Tauopathies

Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer ' s disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of detecting AD at early stages would allow possible therapies to be addressed before the onset of cognitive impairment. Many studies have determined that the expression pattern of some miRNAs is dysregulated in AD patients, but to date, none has been correlated with downregulated expression of cellular prion protein (PrP C ) during disease progression. That is why, by means of cross studies of miRNAs up -regulated in AD with in silico identification of potential miRNAs-binding to 3 ' UTR of human PRNP gene, we selected miR-519a-3p for our study. Then, in vitro experiments were carried out in two ways. First, we validated miR-519a-3p target on 3 ' UTR- PRNP , and second, we analyzed the levels of PrP C expression after using of mimic technology on cell culture. In addition, RT-qPCR was performed to analyzed miR519a-3p expression in human cerebral samples of AD at different stages of disease evolution. Additionally, samples of other neurodegenerative diseases such as other non -AD tauopathies and several synucleinopathies were included in the study. Our results showed that miR-519a-3p overlaps with PRNP 3 ' UTR in vitro and promotes downregulation of PrP C . Moreover, miR-519a-3p was found to be up -regulated exclusively in AD samples from stage I to VI, suggesting its potential use as a novel label of preclinical stages of the disease.

JTD Keywords: 3' untranslated regions, Activation, Aged, Aged, 80 and over, Alzheimer disease, Alzheimer's disease, Biomarke, Biomarker, Biomarkers, Brain, Cellular prion protein, Developmental expression, Female, Gen, Humans, Male, Micrornas, Mirn519 microrna, human, Plasma, Prion proteins, Prnp protein, human, Prpc, Prpc proteins, Tau-aggregation